Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies

Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies

Highlights • Complement is activated in vivo when CD20 mAbs RTX or OFA are infused in CLL patients. • The detailed cellular events that occur in vitro during mAb-mediated CDC have been elucidated for CD20 mAbs. • New and innovative approaches should allow for development of far more effective comple...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Seminars in immunology 2016-06, Vol.28 (3), p.309-316
Hauptverfasser: Taylor, Ronald P, Lindorfer, Margaret A
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Animals
Antibodies, Monoclonal - therapeutic use
Antibody-Dependent Cell Cytotoxicity
Antigens, Neoplasm - immunology
Complement
Complement Activation
Complement System Proteins - metabolism
Cytotoxicity, Immunologic
Genetic Engineering
Humans
Immunotherapy - methods
Immunotherapy of Cancer
Monoclonal antibodies
Neoplasms - immunology
Neoplasms - therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • Complement is activated in vivo when CD20 mAbs RTX or OFA are infused in CLL patients. • The detailed cellular events that occur in vitro during mAb-mediated CDC have been elucidated for CD20 mAbs. • New and innovative approaches should allow for development of far more effective complement-fixing mAbs for cancer immunotherapy.
ISSN:1044-5323
1096-3618
DOI:10.1016/j.smim.2016.03.003